BioCanRx Funded Core Facilities

BioCanRx has awarded funding to four Canadian academic facilities that offer translational services, including one organization that can support commercialization efforts. The Core Facilities program provides a baseline level of support for core facilities to enable their timely and cost-effective use by researchers of BioCanRx-funded projects.

The funded facilities are:

- **Immunotherapy Monoclonal Antibody Platform,** *Montreal Clinical Research Institute (IRCM)*
- **Molecular and Cellular Immunology Core (MCIC)**, *BC Cancer*
- **Biotherapeutics Manufacturing Centre – Virus Manufacturing Facility,** *Ottawa Hospital Research Institute*
- **IRICoR,** Commercialization Support, Université de Montréal

The purpose of this document is to provide greater detail on the funded core facilities. We are happy to support further engagement with Core Facilities for potential collaboration. Please contact Megan Mahoney, Director of Scientific Affairs (memahoney@biocanrx.com).

Immunotherapy Monoclonal Antibody Platform (IMAP)

Montreal Clinical Research Institute

Enabling cutting-edge antibody development for cancer immunotherapy

What is IMAP?

IMAP is a state-of-the-art facility established in 2020 at the IRCM (Institut de recherches cliniques de Montréal) to accelerate the development of monoclonal antibodies (mAbs) for cancer treatment, and is led by Dr. André Veillette.

What do they do?

IMAP generates high-quality mAbs for a range of applications, including:

- Therapeutics (e.g., antibody-drug conjugates, CAR-T cell therapies)
- Diagnostics (e.g., cancer detection and evaluation)
- Research tools (e.g., mechanistic studies, target validation)

*Researchers retain **full intellectual property** on generated mAbs.*

BioCanRx
Canada's Immunotherapy Network
Le réseau canadien d'immunothérapie

IMAP

Capabilities

IMAP generates high-quality mAbs for a range of applications, including:

- Therapeutics (e.g., antibody-drug conjugates, CAR-T cell therapies)
- Diagnostics (e.g., cancer detection and evaluation)
- Research tools (e.g., mechanistic studies, target validation)

*Researchers retain **full intellectual property** on generated mAbs.*

Project Options & Pricing (estimates)

1. Hybridoma Technology (~$6,000/project)

- Immunogen production, immunization, fusion, screening, subcloning, sequencing
- Flexible workflow — projects can be paused at any step

2. Single-Cell RNA Sequencing Approach (~$20,000/project for ~100 clones)

- Ideal for broad antibody screening
- Pricing adjusts based on clone quantity or project scope

3. Optional Services (pricing TBD based on needs):

- mAb sequence cloning
- Humanization or Fc modification
- Generation of specialized formats (e.g., bispecifics, Fc-silent)
- High-yield recombinant mAb production

Why IMAP?

- First-of-its-kind academic mAb facility in Canada
- Access to cutting-edge platforms and expertise
- Accelerates discovery and application of new immunotherapies
- Collaboration opportunities for preclinical to clinical development

To learn more:

IMAP@ircm.qc.ca